MDGL Overview
Upcoming Projects (MDGL)
-
Exploring the Potential of Madrigal Pharmaceuticals' Resmetirom in Treating NASH: Insights from the Phase 3 MAESTRO-NASH Trial
Ticker: MDGL
Execute By: Dec 31, 2023
Executed Projects (MDGL)
-
Exploring the current treatment landscape and the future direction of available NASH specific drugs with the introduction of GLP-1 agonists
Tickers: MDGL, TERN, ETNB, VKTX
Executed On: Sep 19, 2023 at 10:00 AM EDT -
Comparing 89bio's ENLIVEN data (pegozafermin) to Akero's efruxifermin in NASH
Tickers: ETNB, AKRO, MDGL, ICPT
Executed On: Mar 23, 2023 at 02:30 PM EDT -
A Second Look: Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH
Ticker: MDGL
Executed On: Dec 22, 2022 at 01:00 PM EST -
Digging into the recent data from the MAESTRO-NASH phase 3 trial of Madrigal Pharmaceuticals' resmetirom in NASH
Ticker: MDGL
Executed On: Dec 21, 2022 at 03:00 PM EST -
Another view: A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 23, 2022 at 11:00 AM EST -
A look at resmetirom and the upcoming 52 week biopsy results of the phase 3 MAESTRO-NASH trial
Tickers: MDGL, LLY, AKRO, ICPT
Executed On: Nov 18, 2022 at 03:00 PM EST -
A Second Opinion: Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, NVO, MDGL
Executed On: Aug 01, 2022 at 12:00 PM EDT -
Digging into the current and developing treatment landscape for Nonalcoholic steatohepatitis (NASH)
Tickers: ICPT, MDGL, NVO
Executed On: Jul 13, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (MDGL)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (MDGL)
-
Madrigal’s MGL-3196 data released in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) from Phase 2 Clinical Trial
Ticker: MDGL
Occurred on: Dec 06, 2017
Strategic Initiatives (MDGL)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
